Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)

被引：0
|
作者：
Brandes, J.
Kudrow, D.
Klise, S. [1 ]
Krege, J. H.
Case, M. G.
Raskin, J.
Khanna, R. [2 ]
Vasudeva, R.
机构：
[1] Eli Lilly & Co, Missoula, MT USA
[2] Eli Lilly & Co, Windlesham, Surrey, England
来源：
HEADACHE | 2019年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P157
引用
收藏
页码：121 / 121
页数：1
相关论文
共 50 条
  • [31] LONG-TERM EFFICACY OF LANADELUMAB: INTERIM RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Riedl, M.
    Cicardi, M.
    Hao, J.
    Lu, P.
    Li, H.
    Manning, M.
    Bernstein, J.
    Busse, P.
    Tachdjian, R.
    Gower, R.
    Wedner, H.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S30 - S31
  • [32] Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
    Santos, Raul D.
    Duell, P. Barton
    East, Cara
    Guyton, John R.
    Moriarty, Patrick M.
    Chin, Wai
    Mittleman, Robert S.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (09) : 566 - 575
  • [33] Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: Interim results of an open-label extension study
    Ng, Yu-Tze
    Conry, Joan
    Paolicchi, Juliann
    Kernitsky, Lydia
    Mitchell, Wendy
    Drummond, Rebecca
    Isojarvi, Jouko
    Lee, Deborah
    Owen, Randall
    [J]. EPILEPSY & BEHAVIOR, 2012, 25 (04) : 687 - 694
  • [34] An open-label study to evaluate the long-term safety of zelrix™, a sumatriptan iontophoretic patch for the treatment of acute migraine
    Smith, T.
    Pierce, M.
    Griesser, J.
    Sebree, T.
    O'Neill, C.
    [J]. CEPHALALGIA, 2011, 31 (01) : 120 - 120
  • [35] Long-Term, Open-Label Safety Study of Oral Almotriptan 12.5 mg for the Acute Treatment of Migraine in Adolescents
    Berenson, Frank
    Vasconcellos, Elza
    Pakalnis, Ann
    Mao, Lian
    Biondi, David M.
    Armstrong, Robert B.
    [J]. HEADACHE, 2010, 50 (05): : 795 - 807
  • [36] One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: Results of a multicenter, open-label study
    Rothner, AD
    Winner, P
    Nett, R
    Asgharnejad, M
    Laurenza, A
    Austin, R
    Peykamian, M
    [J]. CLINICAL THERAPEUTICS, 2000, 22 (12) : 1533 - +
  • [37] EFFICACY AND SAFETY OF LONG-TERM TREATMENT WITH LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: RESULTS OF A 2-YEAR, OPEN-LABEL EXTENSION STUDY
    Correll, C.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Loebel, A.
    Coghill, D.
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 105 - 105
  • [38] Rimegepant is Safe and Tolerable for the Acute Treatment of Migraine in Patients Using Preventive Migraine Medications: Results from a Long-Term Open-Label Safety Study
    Schim, Jack
    Hutchinson, Susan
    Lipton, Richard
    Croop, Robert
    Stock, Elyse
    Thiry, Alexandra
    Conway, Charles
    Lovegren, Meghan
    Coric, Vlad
    Jensen, Christopher
    [J]. NEUROLOGY, 2021, 96 (15)
  • [39] Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine
    Sakai, Fumihiko
    Takeshima, Takao
    Tatsuoka, Yoshihisa
    Hirata, Koichi
    Cheng, Sunfa
    Numachi, Yotaro
    Peng, Cheng
    Xue, Fei
    Mikol, Daniel D.
    [J]. HEADACHE, 2021, 61 (04): : 653 - 661
  • [40] Assessment of the Long-term Safety and Efficacy of Erenumab During Open-label Treatment of Subjects with Chronic Migraine
    Tepper, S. J.
    Ashina, M.
    Brandes, J.
    Dolezil, D.
    Silberstein, S. D.
    Winner, P. K.
    Zhang, F.
    Cheng, S.
    Mikol, D. D.
    [J]. HEADACHE, 2018, 58 (08): : 1302 - 1303
12345